Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Germany’s Pricing Revolution: Why The World Should Be Watching

Feb 24 2012

Related Content

AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward

Dec 19 2011

German HTA Assessment Knocks Back Gilenya In Europe

Jan 19 2012

For Novartis, 2012 Is Set To Be A Bumpy Ride

Jan 25 2012

AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions

Jan 11 2012

Germany To Disclose Rx Pricing Discounts, Setting A Potential Benchmark For Europe

Feb 07 2012

European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come

Feb 06 2012

Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts

Jul 01 2010

Pharma/Payor Deals An Important Step In The Shift To Value-Based R&D

Dec 27 2011

ACOs Get In Gear, Accelerating Biopharma’s Value Imperative

Feb 24 2012

Intermune’s Esbriet Flops In Front Of IQWiG

Dec 19 2011

German Reimbursement Decisions Will Remain Officially Opaque In New Law

Dec 08 2011

Related Companies

Merck & Co., Inc.

Johnson & Johnson

Vertex Pharmaceuticals Incorporated

InterMune, Inc.

AstraZeneca PLC

Boehringer Ingelheim GmbH

Eli Lilly and Company

Novartis AG

Takeda Pharmaceutical Co. Ltd.

GSK plc

Almirall SA

GW Pharmaceuticals plc

Bausch Health Companies Inc.

Biogen, Inc.

Sanofi

Additional Topics

Europe Germany Clinical Trials Regulation Reimbursement Government Payers Cost Effectiveness BioPharmaceutical

More from Global Vision

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window